Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 221.50
Bid: 220.00
Ask: 222.00
Change: 0.50 (0.23%)
Spread: 2.00 (0.909%)
Open: 220.50
High: 223.50
Low: 218.00
Prev. Close: 221.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PRTC Presents at Two Upcoming Investor Conferences

17 Nov 2022 12:00

RNS Number : 6813G
PureTech Health PLC
17 November 2022
 

17 November 2022

PureTech Health plc

 

PureTech to Present at Two Upcoming Investor Conferences

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com.

 

Piper Sandler 34th Annual Healthcare Conference

Presenters: Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Officer, and Julie Krop, M.D., Chief Medical Officer

Date: Tuesday, November 29, 2022

Time: 1:30 p.m. EST

 

Evercore ISI 5th Annual HealthCONx Conference

Presenter: Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., Chief Medical Officer

Date: Wednesday, November 30, 2022

Time: 8:50 a.m. EST

 

About PureTech Health

PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that will soon be filed for FDA approval, as of the date of PureTech's most recently filed Half-Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the Piper Sandler 34th Annual Healthcare Conference and the Evercore ISI 5th Annual HealthCONx Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com

Investor Relations

IR@puretechhealth.com

 

 

EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

U.S. Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXFKFALAFFA
Date   Source Headline
12th Nov 20202:04 pmRNSSonde Respiratory Portal Available to Developers
11th Nov 20201:03 pmRNSVor Licenses Clinical-Stage CD33 CAR-T Therapy
5th Nov 20207:00 amRNSPureTech Presents at Credit Suisse Conference
3rd Nov 20205:10 pmRNSGelesis Presents New Data at ObesityWeek
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.